Quetiapine - Qrono
Alternative Names: QR 103; Quetiapine QxLatest Information Update: 28 Sep 2021
At a glance
- Originator Qrono
- Class Analgesics; Antidepressants; Antipsychotics; Behavioural disorder therapies; Dibenzothiazepines; Mood stabilisers; Piperazines; Small molecules
- Mechanism of Action 5-HT1 serotonin receptor agonists; 5-HT1A serotonin receptor agonists; Adrenergic receptor antagonists; Adrenergic uptake inhibitors; Alpha 2 adrenergic receptor antagonists; Dopamine D2 receptor antagonists; Serotonin 5-HT2A receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes - Psychiatric disorders
Highest Development Phases
- No development reported Psychiatric disorders
Most Recent Events
- 28 Sep 2021 No recent reports of development identified for preclinical development in Psychiatric-disorders in USA (Parenteral, Injection)
- 16 Aug 2017 Chemical structure information added
- 02 Aug 2017 Quetiapine- Qrono is available for licensing as of 02 Aug 2017. http://qrono.com/pipeline/ (Qrono pipeline, August 2017)